Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Amedisys ha aumentado sus beneficios a una tasa media anual de 3%, mientras que los beneficios de la industria de Healthcare han experimentado un crecimiento de 12.2% anual. Los ingresos han ido creciendo a una tasa media de 6.7% al año. La rentabilidad financiera de Amedisys es de 0.1%, y sus márgenes netos son de 0.1%.

Información clave

3.0%

Tasa de crecimiento de los beneficios

3.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	13.4%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera	0.1%
Margen neto	0.1%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Amedisys. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BMV:AMED * Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Jun 23	2,229	2	280
31 Mar 23	2,234	112	252
31 Dec 22	2,223	119	245
30 Sep 22	2,220	121	244
30 Jun 22	2,216	140	240
31 Mar 22	2,222	191	241
31 Dec 21	2,214	209	237
30 Sep 21	2,206	220	234
30 Jun 21	2,196	247	231
31 Mar 21	2,117	202	220
31 Dec 20	2,072	184	219
30 Sep 20	2,021	166	216
30 Jun 20	1,972	128	214
31 Mar 20	1,980	127	219
31 Dec 19	1,956	127	213
30 Sep 19	1,889	127	207
30 Jun 19	1,812	124	197
31 Mar 19	1,731	123	189
31 Dec 18	1,663	119	185
30 Sep 18	1,626	88	181
30 Jun 18	1,583	71	178
31 Mar 18	1,546	42	178
31 Dec 17	1,511	30	177
30 Sep 17	1,474	43	181
30 Jun 17	1,456	40	187
31 Mar 17	1,438	46	190
31 Dec 16	1,419	37	196
30 Sep 16	1,391	41	198
30 Jun 16	1,358	38	193
31 Mar 16	1,313	38	188
31 Dec 15	1,266	-3	173
30 Sep 15	1,230	-7	158
30 Jun 15	1,204	-7	149
31 Mar 15	1,193	-10	142
31 Dec 14	1,188	13	147
30 Sep 14	1,191	-4	153
30 Jun 14	1,192	-103	161
31 Mar 14	1,203	-109	167
31 Dec 13	1,233	-93	170
30 Sep 13	1,278	-191	176
30 Jun 13	1,340	-90	182
31 Mar 13	1,394	-84	188
31 Dec 12	1,420	-80	190
30 Sep 12	1,441	33	274

Ingresos de calidad: AMED * tiene un gran one-off loss de $109.0M impacto en sus últimos 12 meses de resultados financieros a 30th June, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(0.1%) de AMED * son inferiores a los del año pasado (6.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de AMED * han crecido un 3% al año en los últimos 5 años.

Acelerando crecimiento: AMED * ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: AMED * tuvo un crecimiento negativo de los beneficios (-98.3%) durante el año pasado, lo que dificulta la comparación con la media de la industria Healthcare (17.9%).

Amedisys Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Recent updates

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido